146 related articles for article (PubMed ID: 37187316)
1. Assessing TCR identity, knock-in efficiency, and potency for individualized TCR-T cell therapy.
Camperi J; Devarajan S; McKay A; Tarighat S; Chen D; Hu Z
J Immunol Methods; 2023 Jun; 517():113491. PubMed ID: 37187316
[TBL] [Abstract][Full Text] [Related]
2. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
3. Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response.
He J; Xiong X; Yang H; Li D; Liu X; Li S; Liao S; Chen S; Wen X; Yu K; Fu L; Dong X; Zhu K; Xia X; Kang T; Bian C; Li X; Liu H; Ding P; Zhang X; Liu Z; Li W; Zuo Z; Zhou P
Cell Res; 2022 Jun; 32(6):530-542. PubMed ID: 35165422
[TBL] [Abstract][Full Text] [Related]
4. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.
Matsuda T; Leisegang M; Park JH; Ren L; Kato T; Ikeda Y; Harada M; Kiyotani K; Lengyel E; Fleming GF; Nakamura Y
Clin Cancer Res; 2018 Nov; 24(21):5357-5367. PubMed ID: 29720506
[No Abstract] [Full Text] [Related]
5. Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing.
Lu YC; Zheng Z; Lowery FJ; Gartner JJ; Prickett TD; Robbins PF; Rosenberg SA
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321276
[TBL] [Abstract][Full Text] [Related]
6. A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens.
Hu Z; Anandappa AJ; Sun J; Kim J; Leet DE; Bozym DJ; Chen C; Williams L; Shukla SA; Zhang W; Tabbaa D; Steelman S; Olive O; Livak KJ; Kishi H; Muraguchi A; Guleria I; Stevens J; Lane WJ; Burkhardt UE; Fritsch EF; Neuberg D; Ott PA; Keskin DB; Hacohen N; Wu CJ
Blood; 2018 Nov; 132(18):1911-1921. PubMed ID: 30150207
[TBL] [Abstract][Full Text] [Related]
7. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
[No Abstract] [Full Text] [Related]
8. Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma.
Tan Q; Zhang C; Yang W; Liu Y; Heyilimu P; Feng D; Xing L; Ke Y; Lu Z
J Immunother Cancer; 2019 Aug; 7(1):232. PubMed ID: 31462302
[TBL] [Abstract][Full Text] [Related]
9. Non-viral precision T cell receptor replacement for personalized cell therapy.
Foy SP; Jacoby K; Bota DA; Hunter T; Pan Z; Stawiski E; Ma Y; Lu W; Peng S; Wang CL; Yuen B; Dalmas O; Heeringa K; Sennino B; Conroy A; Bethune MT; Mende I; White W; Kukreja M; Gunturu S; Humphrey E; Hussaini A; An D; Litterman AJ; Quach BB; Ng AHC; Lu Y; Smith C; Campbell KM; Anaya D; Skrdlant L; Huang EY; Mendoza V; Mathur J; Dengler L; Purandare B; Moot R; Yi MC; Funke R; Sibley A; Stallings-Schmitt T; Oh DY; Chmielowski B; Abedi M; Yuan Y; Sosman JA; Lee SM; Schoenfeld AJ; Baltimore D; Heath JR; Franzusoff A; Ribas A; Rao AV; Mandl SJ
Nature; 2023 Mar; 615(7953):687-696. PubMed ID: 36356599
[TBL] [Abstract][Full Text] [Related]
10. Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma.
Bräunlein E; Lupoli G; Füchsl F; Abualrous ET; de Andrade Krätzig N; Gosmann D; Wietbrock L; Lange S; Engleitner T; Lan H; Audehm S; Effenberger M; Boxberg M; Steiger K; Chang Y; Yu K; Atay C; Bassermann F; Weichert W; Busch DH; Rad R; Freund C; Antes I; Krackhardt AM
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518289
[TBL] [Abstract][Full Text] [Related]
11. The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients.
Arnaud M; Bobisse S; Chiffelle J; Harari A
Front Immunol; 2021; 12():701636. PubMed ID: 34394096
[TBL] [Abstract][Full Text] [Related]
12. Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
Plewa N; Poncette L; Blankenstein T
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822673
[TBL] [Abstract][Full Text] [Related]
13. Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma.
Wei T; Leisegang M; Xia M; Kiyotani K; Li N; Zeng C; Deng C; Jiang J; Harada M; Agrawal N; Li L; Qi H; Nakamura Y; Ren L
Oncoimmunology; 2021 May; 10(1):1929726. PubMed ID: 34104546
[TBL] [Abstract][Full Text] [Related]
14. High-throughput identification of antigen-specific TCRs by TCR gene capture.
Linnemann C; Heemskerk B; Kvistborg P; Kluin RJ; Bolotin DA; Chen X; Bresser K; Nieuwland M; Schotte R; Michels S; Gomez-Eerland R; Jahn L; Hombrink P; Legrand N; Shu CJ; Mamedov IZ; Velds A; Blank CU; Haanen JB; Turchaninova MA; Kerkhoven RM; Spits H; Hadrup SR; Heemskerk MH; Blankenstein T; Chudakov DM; Bendle GM; Schumacher TN
Nat Med; 2013 Nov; 19(11):1534-41. PubMed ID: 24121928
[TBL] [Abstract][Full Text] [Related]
15. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
16. Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies.
Kast F; Klein C; Umaña P; Gros A; Gasser S
Oncoimmunology; 2021 Jan; 10(1):1869389. PubMed ID: 33520408
[TBL] [Abstract][Full Text] [Related]
17. Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application.
Xu R; Du S; Zhu J; Meng F; Liu B
Cancer Lett; 2022 Oct; 546():215840. PubMed ID: 35921969
[TBL] [Abstract][Full Text] [Related]
18. Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers.
Li Q; Hu W; Liao B; Song C; Li L
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798537
[TBL] [Abstract][Full Text] [Related]
19. Needle in a Haystack: The Naïve Repertoire as a Source of T Cell Receptors for Adoptive Therapy with Engineered T Cells.
D'Ippolito E; Wagner KI; Busch DH
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33171940
[TBL] [Abstract][Full Text] [Related]
20. Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges.
Pang Z; Lu MM; Zhang Y; Gao Y; Bai JJ; Gu JY; Xie L; Wu WZ
Biomark Res; 2023 Dec; 11(1):104. PubMed ID: 38037114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
